STOCK TITAN

Empower Clinics Stock Price, News & Analysis

EPWCF OTC

Company Description

EMPOWER CLINICS INC (EPWCF) is committed to assisting individuals in improving and safeguarding their health through medical marijuana. With clinics in Washington, Oregon, California, and upcoming in Illinois, they have aided over 200,000 patients since 1999. The company boasts compassionate physicians ready to assist with paperwork and a well-informed staff to guide patients through the process.

Empower is an integrated healthcare company with multi-disciplinary clinics and a Canadian medical device company. They have established a clinical research site in Dallas, TX, becoming a Site Management Organization (SMO). Empower is reshaping patient-first wellness with cutting-edge healthcare and research solutions. Recently, the company announced its plan to consolidate shares and complete a non-brokered private placement offering.

Stock Performance

$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$2.5M
Market Cap
87.5M
Shares outstanding

SEC Filings

No SEC filings available for Empower Clinics.

Financial Highlights

Revenue (TTM)
Net Income (TTM)
Diluted EPS (TTM)
Operating Cash Flow
Net Profit Margin
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the market cap of Empower Clinics (EPWCF)?

The market cap of Empower Clinics (EPWCF) is approximately 2.5M.

What is EMPOWER CLINICS INC known for?

Empower Clinics is dedicated to helping individuals improve and protect their health through the use of medical marijuana.

What are the core services provided by Empower Clinics?

Empower offers multi-disciplinary clinics, a medical device company, and a clinical research site in Dallas, TX.

How many patients has Empower Clinics helped?

Since 1999, Empower has assisted over 200,000 patients across the United States.

What recent corporate updates has Empower Clinics announced?

Empower has revealed plans to consolidate shares, complete a private placement offering, and focus on healthcare AI for clinical trial patient recruitment.